A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples

Projektinformationen

Cancersensing

ID Finanzhilfevereinbarung: 882365

DOI

10.3030/882365

Projekt abgeschlossen

EK-Unterschriftsdatum 29 November 2019

Startdatum 1 November 2019

Enddatum 29 Februar 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

MDB DIAGNOSIS GROUP LIMITED
United Kingdom

Periodic Reporting for period 1 - Cancersensing (A multi-cancer screening platform for fast and accurate early stage cancer detection from urine samples)

Berichtszeitraum: 2019-11-01 bis 2020-02-29

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

MDB Diagnosis (MDBD) is a UK-based Company founded in 2018 with the goal of making available to society a universal test to be used as a tool in large-population screening for early diagnosis of all cancer types. MDBD developed Cancersensing, a unique cancer screening platform capable of detecting multiple types of cancer simultaneously by exploiting a single urine sample. Thanks to its unique sensitivity and specificity, and its cost-effectiveness, Cancersensing is an ideal tool for cancer screening aimed at detecting the disease before symptoms arise. The team is now working towards the optimisation of the platform to enable its application for large population cancer screening application. Key objectives of the development are 1) design and validate a kit for standardizing sample processing and 2) enable cloud-accessibility to the analysis software to empower every diagnostic lab to perform the test; 3) expand the range of types of cancers detected by the test 3) validate the whole platform on a large scale and 4) obtaining CE mark certification for commercialization in Europe.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Throughout the duration of the feasibility assessment, MDBD defined the customer&users’ requirements for the Cancersensing platform, reviewed the product development plan, defined the scale-up activities, and scouted for key stakeholders to support in the in-field validation. The market segments and opportunities have also been evaluated, defining the TAM and SAM, and a commercialisation strategy has been established. The Phase 1 feasibility assessment showed a compelling opportunity for the project, confirming the technical and commercial viability of Cancersensing. The EIC Accelerator Phase 2 funding could provide the needed amount of funding and support for the successful implementation of the planned activities.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

In 2020, there will be over 10 million cancer deaths. Since late diagnosis is the major factor associated with cancer mortality, many of these million lives could have been prevented with efficient and comprehensive screening programs enabling early detection of cancer. Cancersensing detects the most common cancer types with a simple, inexpensive urine test that can be implemented within routine annual check-up visits, enabling large comprehensive cancer screening programs for everyone.
Beyond the societal burden, cancer generates a global economic burden exceeding €1.07 trillion annually (due to treatment costs as well as the cost of premature death and disability). A large fraction of this huge cost could be prevented with effective screening strategies and reallocated for the benefit of everyone. Such figures are further exacerbated by the fact that a 70% increase in cancer incidence is anticipated over the next couple of decades, mainly due to the global rise in the geriatric population (anticipated to nearly double from 12% to 22% by 2022 only).

image-for-summary.jpg